| abstract |
Recombinant glycoproteins having altered (eg, improved) glycosylation profiles (eg, recombinant human α-galactosidase-A protein), and pharmaceutical compositions and kits comprising one or more of these proteins are described herein. Provided in the specification. A method for producing mammalian cells useful for recombinant expression of a glycoprotein (eg, recombinant human α-galactosidase-A), a method for producing the recombinant protein, and at least one recombinant glycoprotein (eg, recombinant human α A method of treatment comprising administering a galactosidase-A protein) is also provided. |